Hello!
#AIChat is a 10-15 minute maximum Twitter chat on artificial intelligence (AI).
Where my guest(s) and I help you figure out what’s going in the AI world.
And give you some ideas on how you can use it at work. Or in your life.
Today’s guest?
Dr. Sophia Ononye-Onyia, PhD, MPH, MBA (her Twitter handle? @drsophiao)
The topic?
How AI can be used in life sciences.
Mistakes are mine.
——-
#AIChat starts at 2PM ET!
With my guest @drsophiao!
Talking how #AI can impact life sciences industry!— Nick Tang (@nickhtang) August 27, 2020
#AI can be used to improve the discovery new drugs for #infectiousdisease anti-infectives, especially now that we are dealing with #COVID19. #AI is being used to identifying patterns in #BigData and generating illuminating algorithms.
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
Also, search engines driven by #AI are becoming increasingly popular in our fight against the coronavirus. #FemTech
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
For example, @Google’s COVID-19 Research Explorer tool when prompted with basic research questions will return a list of research papers with highlighted relevant sections that ease the drug discovery process.
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
The simple #fact that there are over 200 #lifescience startups globally who are using #AI for drug discovery also shows the #power of this #technology.
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
La Jolla-based @Data4Cure whose technology is designed to identify new targets and biomarkers, repurpose drugs and identify disease pathways that may be improved with combination therapy.
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
In late 2019, @Novartis, a #BigPharma company, and @Microsoft announced their plans to “bring the power of #AI to the desktop of every @Novartis associate” and “to tackle some of the hardest computational challenges within #lifesciences.”
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
In many ways, both companies were ahead of the curve in realizing the importance of user familiarity and maximizing the use and adoption of #AI for #publichealth.
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
Overall, I’m super excited about the future of #AI in #lifesciences
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
The advantages are faster drug discovery time periods, potentially lower #drugprices due to more effective clinical trials, more personalized drugs for patients. #AI #femtech
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
Follow up: is this where #AI will excel @drsophiao? In the personalized drugs for patients (like the entertainment industry’s use of #AI)?
— Nick Tang (@nickhtang) August 27, 2020
Absolutely. No two humans are exactly the same so why should we all take the same drugs? #personalizedmedicine #genetherapy #celltherapy #AICHAT
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
Germany’s @Molecular Health’s #AI platform can potentially improve the prediction of drug response and resistance and design more successful #clinicaltrials.
— Sophia Ononye-Onyia, PhD MPH MBA (@drsophiao) August 27, 2020
